Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use

Breast Cancer Research and Treatment

Volumn 139, Issue 2, 2013, Pages 507-513

  Holmes, Michelle D ^a,b   Hankinson, Susan E ^a,b,c   Feskanich, Diane ^a   Chen, Wendy Y ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adrenergic beta antagonists; Angiotensin converting enzyme inhibitors; Aspirin; Breast neoplasms; Survival

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878747207     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2553-7     Document Type: Article

References (21)

1. Holmes MD, Chen WY (2012) Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res 14(2):216. doi: 10.1186/bcr3336
2. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6(3):240-248. doi: 10.1038/nrc1820
3. Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011) Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130(2):177-190. doi: 10.1016/j.pharmthera.2011.01.009
4. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042-7052. doi: 10.1158/0008-5472.CAN-10-0522
5. Vandewalle B, Revillion F, Lefebvre J (1990) Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116(3):303-306
6. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628-638
7. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-2652. doi: 10.1200/JCO.2010.33.4441
8. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. doi: 10.1007/s10549-011-1505-3
9. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29(19):2635-2644. doi: 10.1200/JCO.2010.33.5422
10. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, Wulff C (2008) Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 109(3):418-425. doi: 10.1016/j.ygyno.2008.02.019
11. Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC (2003) Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 63(3):573-578
12. Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC (2005) Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 26(2):459-464. doi: 10.1093/carcin/bgh309
13. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, Manca C, Marsigliante S (2003) Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196(2):370-377. doi: 10.1002/jcp.10313
14. Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S (2010) Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. J Cell Physiol 225(1):168-173. doi: 10.1002/jcp.22209
15. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Investig 29(9):585-593. doi: 10.3109/07357907.2011.616252
16. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol. doi: 10.1200/JCO.2009.22.7918
17. Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, Tamimi RM (2011) COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 130(2):657-662. doi: 10.1007/s10549-011-1651-7
18. Kwan ML, Habel LA, Slattery ML, Caan B (2007) NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18(6):613-620. doi: 10.1007/s10552-007-9003-y
19. Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101(2):191-197. doi: 10.1007/s10549-006-9277-x
20. Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. doi: 10.1016/S1470-2045(12)70112-2
21. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591-1601. doi: 10.1016/S0140-6736(12)60209-8